Pramlintide vs Exenatide

Pramlintide and exenatide were both approved in 2005 as injectable adjuncts in diabetes but target different hormones — amylin and GLP-1 — that both slow gastric emptying and reduce glucagon after meals.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Pramlintide

A synthetic analogue of the pancreatic hormone amylin, the first approved amylinomimetic.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

Exenatide

A synthetic version of exendin-4, a 39-amino-acid peptide from Gila monster venom and the first GLP-1 receptor agonist approved as a medicine.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

SIDE BY SIDE

	Pramlintide	Exenatide
The key difference	Amylin analogue	GLP-1 receptor agonist
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Amylin is co-secreted with insulin; it lowers post-meal glucose by suppressing glucagon, slowing gastric emptying and reducing food intake.	Exendin-4 shares about 53% homology with GLP-1 but resists DPP-4 degradation.
Status	Approved (2005, US) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. The scientific ancestor of cagrilintide.	Approved for type 2 diabetes (twice-daily and weekly forms); extensively used in preclinical research including neuro and β-cell studies.
Reported safety signals	Hypoglycaemia risk when combined with insulin is the key labelled concern; a randomised study found it could provoke migraine-like attacks in migraine patients.	Nausea is the characteristic early effect; reviews cover pharmacokinetics, adverse effects and interactions.
A key study	Reviews pramlintide as the first amylinomimetic, approved in 2005 as an insulin adjunct. (Am J Health Syst Pharm 2005, PMID 16278328)	Reviews exenatide’s pharmacology, pharmacokinetics, efficacy and adverse effects; derived from Gila monster saliva. (Am J Health Syst Pharm 2006, PMID 16484515)

WHEN TO RESEARCH WHICH

They represent the two earliest non-insulin peptide approaches to post-meal glucose control. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Pramlintide] Pramlintide acetate — Am J Health Syst Pharm 2005. PMID 16278328
[Pramlintide] Pramlintide in the treatment of type 1 and type 2 diabetes mellitus — Clin Ther 2005. PMID 16330288
[Pramlintide] Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients — Ann Neurol 2021. PMID 33772845
[Exenatide] Exenatide — Am J Health Syst Pharm 2006. PMID 16484515
[Exenatide] Exenatide. Amylin/Eli Lilly — Curr Opin Investig Drugs 2003. PMID 12808888
[Exenatide] Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system — Sci Transl Med 2024. PMID 38985854

FREQUENTLY ASKED

What is the difference between Pramlintide and Exenatide?

What is the regulatory status of Pramlintide and Exenatide?

Pramlintide: Approved (2005, US) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. The scientific ancestor of cagrilintide. Exenatide: Approved for type 2 diabetes (twice-daily and weekly forms); extensively used in preclinical research including neuro and β-cell studies.

What safety signals have been reported?

Pramlintide: Hypoglycaemia risk when combined with insulin is the key labelled concern; a randomised study found it could provoke migraine-like attacks in migraine patients. Exenatide: Nausea is the characteristic early effect; reviews cover pharmacokinetics, adverse effects and interactions.

Which studies is this comparison based on?

For Pramlintide: “Pramlintide acetate” (PMID 16278328); “Pramlintide in the treatment of type 1 and type 2 diabetes mellitus” (PMID 16330288); “Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients” (PMID 33772845). For Exenatide: “Exenatide” (PMID 16484515); “Exenatide. Amylin/Eli Lilly” (PMID 12808888); “Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system” (PMID 38985854).